Key Insights

Highlights

Success Rate

77% trial completion

Published Results

23 trials with published results (31%)

Research Maturity

55 completed trials (73% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

21.3%

16 terminated out of 75 trials

Success Rate

77.5%

-9.0% vs benchmark

Late-Stage Pipeline

7%

5 trials in Phase 3/4

Results Transparency

42%

23 of 55 completed with results

Key Signals

23 with results77% success16 terminated

Data Visualizations

Phase Distribution

74Total
Not Applicable (7)
Early P 1 (1)
P 1 (35)
P 2 (26)
P 3 (5)

Trial Status

Completed55
Terminated16
Withdrawn4

Trial Success Rate

77.5%

Benchmark: 86.5%

Based on 55 completed trials

Clinical Trials (75)

Showing 20 of 20 trials
NCT00826540Phase 2CompletedPrimary

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01814501Phase 2Completed

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

NCT00019006Phase 1CompletedPrimary

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

NCT00407654Phase 2CompletedPrimary

VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer

NCT01769222Phase 1Terminated

Ipilimumab and Local Radiation for Selected Solid Tumors

NCT00019760Phase 2CompletedPrimary

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

NCT02232152Phase 1Completed

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT03602079Phase 1Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT01285102Phase 1Terminated

Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer

NCT01987726Completed

Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors

NCT01807117Not ApplicableCompletedPrimary

PET-MRI in Diagnosing Patients With Colon or Rectal Cancer

NCT01037790Phase 2Completed

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

NCT01846520Not ApplicableCompleted

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

NCT01806675Phase 1Completed

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

NCT00397878Phase 2Terminated

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer

NCT00645710Phase 1Completed

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

NCT01923337Phase 1Completed

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

NCT01590147Not ApplicableCompleted

Supportive Intervention Programs Study

NCT01126346Not ApplicableCompleted

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT02110953Phase 1Terminated

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

Scroll to load more

Research Network

Activity Timeline